Lung neoplasia is a major cause of death in cancer patients throughout the world. Diagnostic techniques and therapeutic modalities for lung cancer patients have been improved over the past decade; however, the overall death rate is still high. 1) Despite undergoing curative surgical treatment, many patients develop recurrent disease and most of such recurrent disease includes distant metastasis.
Lung neoplasia is a major cause of death in cancer patients throughout the world. Diagnostic techniques and therapeutic modalities for lung cancer patients have been improved over the past decade; however, the overall death rate is still high. 1) Despite undergoing curative surgical treatment, many patients develop recurrent disease and most of such recurrent disease includes distant metastasis.
2, 3) Therefore, controlling metastatic disease is one of the important problems that must be addressed in order to conquer lung neoplasia.
Among the various clinicopathological factors, lymphatic metastasis is one of the most critical factors for the prognosis of lung cancer patients. [4] [5] [6] Although experimental models for lung cancer have been reported by several investigators, these models have included some important drawbacks, such as ectopic implantations and complicated procedures. [7] [8] [9] Recently, we established a model of spontaneous lymphatic metastasis produced by orthotopic implantation of lung cancer cells. 10) Direct implantation of Lewis lung carcinoma (LLC) admixed with "MATRIGEL" into the left lobe of the lung caused the formation of a solitary tumor followed by metastasis to the mediastinal lymph node. This model should be useful for investigating therapeutic approaches for lung cancer disease in preclinical studies.
We have reported that 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid, TAC-101, abolished activating protein-1 (AP-1) binding to consensus DNA and inhibited the experimental liver metastasis of gastrointestinal tract cancer in animal models.
11) AP-1 has been reported to be a major transcriptional enhancer for the expression of urokinase-type plasminogen activator, overexpression of which has been reported to be correlated with lymphatic metastasis of lung cancer. [12] [13] [14] [15] [16] In the present study, we investigated the effects of TAC-101 on the growth at the implantation site and the spontaneous lymphatic metastasis caused by the orthotopic implantation of LLC, and we examined its anti-metastatic mechanism of action in vitro. Since platinum agents have been used as standard treatment modalities for lung cancer, 1, 17, 18) combination therapy of TAC-101 and CDDP in the LLC model was also examined. Intrapulmonary implantation of LLC and evaluation of anti-tumor activity Orthotopic implantation of LLC cells into the lung was performed as described previously with some modification. 10) The left chests of anesthetized mice were incised (approximately 5 mm in length) and 20-µl aliquots of LLC cell suspension (2×10 3 cells) admixed with "MATRIGEL" (Collaborative Biochemical Products Inc., MA; 20 µg) were injected into the left lung parenchyma through the intercostal space. The skin incision was closed with "AUTOCRIP" (Becton Dickinson Co., MD). The anti-tumor effect was evaluated by measuring the weight of orthotopic tumor in the lung and the metastasized tumor at mediastinal lymph nodes on day 17 after the implantation. The survival time (days) of mice after the implantation was determined to evaluate the life-prolonging effect. In vivo treatment with TAC-101 and CDDP TAC-101 was administered p.o. daily for 14 days, starting on day 1 after tumor implantation. CDDP (7 mg/kg), a clinically equivalent dose in mice, 19) was given i.v. on day 1. In the experiments with combination treatment, CDDP was given i.v. on day 1 and TAC-101 was given p.o. for 14 days starting on day 1. Invasion assay The invasive ability of tumor cells was assessed in a Chemotaxicell chamber (Kurabo Inc., Osaka; 8-µm pores) as described previously. 20) Filters of the chamber were coated with 1 µg/10 µl of fibronectin (Iwaki Glass Co., Ltd., Tokyo) on the lower surface and 10 µg/50 µl of "MATRIGEL" on the upper surface and dried. LLC cells suspended in DMEM/F-12 with 0.1% bovine serum albumin (BSA) (1×10 5 /chamber) were added to the upper compartment of the chamber, and incubated in the presence of various concentrations of TAC-101 in both upper and lower compartments. After 24 h of incubation, the invaded cells on the lower surface of the chamber were determined by crystal violet staining. Each condition was tested in quadruplicate. Assay for in vitro cytotoxic activity LLC cells were resuspended in DMEM/F-12 supplemented with 10% FCS, and seeded into 96-well culture plates (2×10 3 /well). After 48 h of preincubation, the medium was replaced with DMEM/F-12 containing 0.1% BSA and various concentrations of TAC-101, and the cultures were incubated for a further 24 h. Crystal violet staining was performed to evaluate the activity. Zymographic assay for urokinase-type plasminogen activator (u-PA) u-PA activity was detected using zymography as previously described. 21) LLC cells (5×10 4 / well) suspended in DMEM/F-12 supplemented with 10% FCS were seeded into 24-well culture plates. After a 24-h preincubation, the medium was replaced with DMEM/F-12 containing 0.1% BSA plus various concentrations of TAC-101, and the cultures were incubated for a further 24 h. Aliquots of conditioned medium (20 µg of protein) were electrophoresed on fibrinogen (Nacalai Tesque, Osaka)-containing gels and incubated for 48 h at 37°C. Fibrinolytic activities were quantified using a Master Scan Gel Analysis System (Scanalytics, Billerica, MA).
MATERIALS AND METHODS

Chemicals
Reverse transcriptase-polymerase chain reaction (RT-PCR) LLC cells (2×10
5
/well) suspended in DMEM/F-12 supplemented with 10% FCS were seeded into 6-well culture plates and preincubated for 48 h. After preincubation, the medium was replaced with fresh DMEM/F-12 containing 0.1% BSA and TAC-101, and then incubation was continued for 3, 6, 12 or 24 h. Total RNA was isolated using "ISOGEN" (Nippon Gene Inc., Tokyo). Five micrograms of isolated RNA was reverse-transcribed using a First Strand cDNA Synthesis Kit (Life Science Inc., FL) at 42°C (45 min) to maximize cDNA synthesis, and terminated by heating at 99°C (5 min). PCR was performed using cDNA templates (contamination of genomic DNA was not observed in a preliminary experiment; data not shown) and specific oligonucleotide primers for u-PA, u-PAR, PAI-1, PAI-2 22) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 23) as described previously. The relative abundances of u-PA, u-PAR and PAI-1 were expressed as density ratios relative to GAPDH, as determined by using the Master Scan Gel Analysis System (Scanalytics, Billerica, MA). Dual reporter assay for evaluation of AP-1 activity LLC cells (2×10 5 /well) suspended in DMEM/F-12 with 10% FCS were seeded into 6-well culture plates. After 48 h of preincubation, pAP-1 Luc plasmid (Stratagene, Funakoshi, Tokyo, 1 µg/well) and pRL-TK vector (Promega Co.,WI; 0.1 µg/well) were cotransfected using FUGENE 6 reagent (Roche Diagnostics, GmbH, Mannheim, Germany) and incubation was continued for a further 20 h. The medium of transfected cells was replaced with DMEM/F-12 containing 0.1% BSA plus various concentrations of TAC-101, and the culture was incubated for a further 6 or 24 h. At the end of the incubation, cell lysates were prepared and AP-1 luciferase activity was determined by using the "Dual-Luciferase" Reporter Assay System (Promega Co., MA). The relative AP-1 activity was determined using the pRL-TK luciferase activity as an internal control. Statistics Welch's t-test for continuous data 24) and Wilcoxon's exact test for discrete data 25) were performed as two-sided tests. Dunnett's t-test was performed as a twosided test in order to decrease the multiplicity in comparisons of drug-treated groups with controls. 26) To analyze the statistical significance of combination therapy, one-sided Welch's t-test for tumor weight and one-sided Wilcoxon's exact test for survival time were performed using the all rejecting rule against an a-priori ordered hypothesis, comparing TAC-101 alone and CDDP alone with combined drug treatment.
27)
RESULTS
Effect of TAC-101 on the growth of the inoculated tumor and lymph node metastasis after orthotopic implantation of LLC Daily oral administration of TAC-101 slightly inhibited the growth of LLC tumors at the implantation site (Fig. 1A) . The inhibitory effect of 16 mg/ kg TAC-101 was significant (inhibition rate=46%). On the other hand, metastasis to the mediastinal lymph nodes was significantly inhibited by TAC-101 in a dose-dependent manner in the dose range from 4 to 16 mg/kg (Fig. 1B : inhibition rate=57 to 76%). Mice treated with vehicle, 2 and 16 mg/kg of TAC-101 showed a reduction of body weight from day 10 after implantation, whereas the administration of 4 and 8 mg/kg TAC-101 prevented the loss of body weight in tumor-bearing mice (Fig. 1C) . Thus, appropriate concentrations of TAC-101 can prevent the loss of body weight in tumor-bearing mice. Since 16 mg/ kg of TAC-101 showed anti-tumor and anti-metastatic effects without preventing the reduction of body weight, lack of a positive effect on body weight may have been due to drug-induced toxicity. Therefore, in the following experiments, we used 8 mg/kg TAC-101, since it appeared to be the optimal dose in this model, as was previously reported.
11)
Combined effect of CDDP and TAC-101 in the lung cancer model As shown in Fig. 2A , combined treatment with TAC-101 (8 mg/kg) and CDDP (7 mg/kg) significantly inhibited tumor growth in the lung as compared to treatment with each drug alone. TAC-101 also produced a significant inhibition of lymph node metastasis, while CDDP alone did not inhibit metastasis (Fig. 2B) . However, the anti-metastatic activity of CDDP was enhanced by the combination with TAC-101. Combination with TAC-101 did not enhance the loss of body weight caused by CDDP treatment (Fig. 2C) . We next examined the lifeprolonging effect achieved with the combined treatment modality (Fig. 3) . All the untreated control mice died of tumor burden within 26 days after the implantation. Similar enhanced survival rates were observed in the group of mice which had received either TAC-101 or CDDP alone. The group which received CDDP and TAC-101 showed a significantly prolonged survival time. The T/C values of survival time in TAC-101, CDDP and the combined treatment groups were 124, 118 and 180%, respectively. These findings clearly indicate that the combination of TAC-101 and CDDP showed an increased therapeutic effect on tumor metastasis and survival rate. In vitro effect of TAC-101 on tumor invasion and invasion-related molecules To examine the anti-metastatic properties of TAC-101, invasion assays were performed using "MATRIGEL." TAC-101 at non-cytotoxic concentrations of less than 10 µM showed dose-dependent inhibition of the invasion of LLC cells (Fig. 4) . Because blocking of the u-PA/plasminogen system is able to inhibit LLC cell invasion, [28] [29] [30] we next examined the effect of TAC-101 on the production of u-PA. As shown in Fig. 5A , two fibrinolytic bands were detected at approximately 100 kDa and at 55 kDa in the zymogram. Since it has been reported that there are four bands i.e., u-PA/PAI-1 complex, tissue-type plasminogen activator, high-molecular-weight u-PA (free form of full-size mature u-PA) and low-molecular-weight u-PA of approximately 100, 70, 55 and 33 kDa, respec- tively, in fibrinolytic zymograms, 31) the fibrinolytic bands of 100 kDa and 55 kDa were considered to be the PAI-1-bound and free forms of u-PA, respectively. Both fibrinolytic bands disappeared after treatment with TAC-101 in a concentration-dependent manner (Fig. 5, A and B) . RT-PCR showed that LLC expressed mRNA for u-PA, u-PAR and PAI-1, but not for PAI-2 (Fig. 6) . Treatment with TAC-101 for 3, 6, 12 or 24 h resulted in a significant decrease of the mRNA for u-PA and u-PAR (Fig. 7) . Thus, TAC-101 inhibited the production of u-PA through reducing the mRNA for u-PA. Moreover, reduction of the mRNA for u-PAR by TAC-101 may be involved in the inhibition of anti-invasive ability by TAC-101. Anti-AP-1 activity of TAC-101 The gene expression of u-PA is considered to be transactivated by AP-1, because AP-1 binding motifs are located in the promoter regions of u-PA, as well as u-PAR.
14, 32) Since we previously reported that TAC-101 inhibited the binding of AP-1 to its consensus DNA, 11) inhibition of AP-1 activity by TAC-101 was also examined using the dual luciferase assay system. Treatment with TAC-101 for transfected LLC cells (6 h) inhibited AP-1 transcriptional activity in a concentrationdependent manner (Fig. 8A) . Ten micromolar TAC-101 significantly decreased AP-1 activity at both 6 and 24 h (Fig. 8B) , which suggests that inhibition of u-PA and u-PAR expression by TAC-101 is mediated by reduction of AP-1 activity.
DISCUSSION
The present study demonstrated the anti-tumor effect of TAC-101 on the orthotopic tumor growth and mediastinal lymph node metastasis of LLC caused by intrapulmonary implantation and also examined anti-AP-1 activity of TAC-101. TAC-101 potently inhibited the metastatic growth of LLC at mediastinal lymph nodes rather than the growth of the tumor at the implantation site (Fig. 1) . TAC-101 also inhibited the invasion of LLC cells in vitro (Fig.  4) . Downregulation of u-PA and u-PAR expressions due to inhibition of AP-1 activity is considered to be associated with anti-invasive and anti-metastatic effects of TAC-101 (Figs. 5, 7 and 8) .
The u-PA/plasminogen system is thought to be involved in the development of metastatic disease through fibrinolytic degradation of extracellular matrix, activation of growth factors and mitogen for tumor cells and vascular endothelial cells. 33) Increased expression of u-PA is observed in various types of cancers and is related to the metastatic potential. 34) In some cases of lung cancer, the prognosis of patients with high expression of u-PA is reported to be significantly worse than that of patients with lower expression of u-PA. 35) Lymphatic metastasis of lung cancer is correlated with enhanced expression of u-PA. 36, 37) It has been reported that the invasion and metastasis of LLC cells were inhibited by blocking the u-PA/ plasminogen system. [28] [29] [30] In addition, the c-Jun proto-oncogene product, which is a component of transcription factor AP-1, is also overexpressed in lung cancer patients with metastasis. 38, 39) AP-1 is a major transcriptional enhancer for the transactivation of u-PA and u-PAR genes, expression of which is dependent on the activation of AP-1, although another factor, PEA3, binds to their promoter region. [12] [13] [14] [15] [16] 32) AP-1 also regulates other matrix-degrading enzymes, 40) though our preliminary experiment suggested that LLC cells did not express a major metastasis-associated gene, MMP-9 (data not shown), which contains an AP-1-binding site on the promoter region. Moreover, AP-1 antagonism has been reported to cause a decrease of in vivo tumorigenesis. 41) These findings suggest that the anti-AP-1 activity of TAC-101 resulted in growth inhibition of the metastatic lymph node tumor due to repression of AP-1-related genes such as u-PA and u-PAR.
The prognosis of lung cancer patients who have recurrent metastatic disease is generally poor.
1, 42) Among the potent combined modalities, platinum-based chemotherapy is used as a standard modality for treatment of lung cancer patients. 17, 18) Thus, we investigated the combined therapeutic effects of TAC-101 and CDDP in the LLC model. As shown in Fig. 2 , TAC-101 alone caused a significant inhibition of mediastinal lymph node metastasis, while CDDP alone did not inhibit metastasis. Combination treatment with TAC-101 and CDDP caused an increased antitumor effect against both proliferation of the tumor at the implantation site and lymph node metastasis. Although the mechanism of the marked combined effect against tumor growth in the lung remains to be elucidated in detail, u-PA reduction by TAC-101 may be partly associated with the suppression of tumor neovascularization, because interaction between u-PA and its receptor appears to be mandatory for the angiogenic effect of u-PA. 43) Furthermore, this combined treatment significantly prolonged the survival time of mice as compared with treatment with each agent alone (Fig. 3) . These findings suggest that this combined treatment with TAC-101 and CDDP delays the progression of lymphatic metastasis of lung cancer, even though the mechanisms of action of TAC-101 and CDDP are independent of each other.
In conclusion, TAC-101 inhibited spontaneous lymphatic metastasis of murine lung cancer. The combination of TAC-101 and CDDP caused marked anti-tumor and life-prolonging effects. TAC-101, which has anti-metastatic properties based on repression of AP-1 activity, may offer improved therapeutic efficacy for patients with lymphatic metastasis of lung cancer. 2) Regnard, J. F., Santelmo, N., Romdhani, N., Gharbi, N., Bourcereau, J., Dulmet, E. and Levasseur, P. Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors. Chest, 114, 45-50 (1998). 
